Recent Updates
Recently added Catalysts
VNRX Positive Sentiment

Identification of an epigenetic profile of circulating nucleosomes in Non-Hodgkin Lymphoma as potential biomarkers of the disease

Monday, March 4, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The poster presented at CNAPS 2024 by Donis et al. discusses the identification of an epigenetic profile of circulating nucleosomes in Non-Hodgkin Lymphoma. This research suggests that these profiles may serve as potential biomarkers for the disease, offering insights into prognostic value. The findings could enhance diagnostic and therapeutic strategies in oncology.
Price reaction · baseline $20.8 (2024-03-01 close) · hit pre-market · 4 other VNRX headline(s) in the window, move may be shared
day 0 close
-2.9%

Market Sentiment Analysis

POSITIVE FACTORS

  • Identification of epigenetic profiles could lead to new biomarkers.
  • Potential for improved prognostic tools in Non-Hodgkin Lymphoma.
  • Research presented at a notable conference (CNAPS 2024).

Full Press Release Details

Poster titled: “Identification of an epigenetic profile of circulating nucleosomes in Non-Hodgkin Lymphoma as potential biomarkers of the disease.”
Presented at CNAPS 2024
Donis et al

Related Articles

• Press Releases Data Showing the Prognostic Value of its Nu.Q® Cancer Test
• Poster & Publications Cytokine-induced chromatin accessibility in whole blood neutrophils links to sepsis transcriptional states

Data Showing the Prognostic Value of its Nu.Q® Cancer Test

Cytokine-induced chromatin accessibility in whole blood neutrophils links to sepsis transcriptional states

• Share
• Tweet
• Share on Facebook
• Share

Subscribe for Volition product updates .

Or, click here for Investor Updates and press releases .

" * " indicates required fields

Frequently Asked Questions

What was the focus of the CNAPS 2024 poster?

The poster focused on identifying an epigenetic profile of circulating nucleosomes in Non-Hodgkin Lymphoma.

Who presented the research at CNAPS 2024?

The research was presented by Donis et al.

What potential do the identified biomarkers have?

The identified biomarkers may improve prognostic tools for Non-Hodgkin Lymphoma.

What type of cancer is discussed in the article?

The article discusses Non-Hodgkin Lymphoma.

ShareAdd on Google
Tags: VNRX Viatris Investor Conferences Healthcare Non-Hodgkin Lymphoma biomarkers epigenetic profile circulating nucleosomes CNAPS 2024
Last updated: Mar 4, 2024

Biotech snapshot

Cash runway
$3M liquidity · $2M/mo burn
~1 mo
High dilution risk